Story

Revolution Medicines Wins FDA Approval for Pancreatic Cancer Drug Rasonque

ENTHMSVIIDZHZH-TWJAKOHI
Aug 26, 20262 min read
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Drug Rasonque
Text size
Background

Revolution Medicines has received U.S. Food and Drug Administration (FDA) approval for its targeted therapy Rasonque, a new treatment for patients with advanced pancreatic cancer. The drug demonstrated in a large trial that it could double the survival rate for patients with the disease, which has one of the lowest survival rates among cancers.

Approval and Indication

The FDA approved Rasonque, a once-daily pill, for patients with metastatic pancreatic cancer who have either received prior treatment or are unable to undergo combination chemotherapy. The therapy works by blocking several forms of the RAS protein, a key driver of tumor growth in many pancreatic cancers, according to the announcement.

The drug was reviewed under the FDA's expedited review process, designed to shorten approval timelines for therapies that address significant unmet medical needs. This accelerated path can reduce the typical 10-to-12-month review to as little as one to two months.

Addressing a High Unmet Need

Pancreatic cancer is one of the most lethal forms of cancer, with a five-year survival rate of approximately 13%, as reported by the American Cancer Society. The organization estimates that about 67,350 people will be diagnosed with the disease in the U.S. this year.

Demand for the drug was high even before the formal approval. The FDA had granted early access to Rasonque through its compassionate use program, also known as the Expanded Access Program, which allows patients with life-threatening conditions to receive experimental treatments. According to a report from Reuters, more than 2,000 patients were already enrolled in this program.

Sample IUX Markets – In-articleAd

Market Impact and Analyst Projections

Investors have anticipated the drug's approval, driving shares of Revolution Medicines (RVMD) up 166% this year. The stock was relatively flat following the widely expected announcement.

Analysts at RBC Capital Markets project a strong commercial launch, supported by the patients already receiving the therapy. They forecast potential revenue from the drug could include:

  • $28 million in U.S. pancreatic cancer sales in the third quarter.
  • $148 million in fourth-quarter sales.
  • $11.5 billion in peak annual sales long-term.

RBC analysts noted that the drug's "impressive data and unmet need" could support premium pricing. Revolution Medicines has not yet commented on the drug's pricing or availability.

Read next

More on Stocks
Back to latest news

LATEST